# A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia

> **NCT01791725** · PHASE2 · COMPLETED · sponsor: **OPKO Health, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Down Syndrome

## Interventions

- **DRUG:** ELND005
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01791725
- **Lead sponsor:** OPKO Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2019-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01791725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01791725, "A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT01791725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*